LivaNova (NASDAQ:LIVN) Price Target Raised to $70.00

LivaNova (NASDAQ:LIVN) had its price objective raised by Robert W. Baird from $63.00 to $70.00 in a research note published on Thursday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Other research analysts have also recently issued reports about the company. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. Barclays boosted their target price on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of LivaNova in a report on Wednesday, September 3rd. Finally, Mizuho increased their price objective on shares of LivaNova from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $62.43.

LivaNova Trading Up 0.3%

LivaNova stock opened at $55.36 on Thursday. The firm has a 50 day moving average of $53.71 and a 200 day moving average of $48.93. LivaNova has a 12-month low of $32.48 and a 12-month high of $58.91. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -14.23 and a beta of 1.00. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, November 5th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.20. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $357.80 million during the quarter, compared to analyst estimates of $342.32 million. During the same quarter last year, the business posted $0.90 EPS. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. As a group, research analysts predict that LivaNova will post 2.85 earnings per share for the current year.

Hedge Funds Weigh In On LivaNova

Hedge funds have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. increased its position in shares of LivaNova by 6.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 46,833 shares of the company’s stock worth $1,840,000 after purchasing an additional 2,901 shares during the last quarter. New York State Common Retirement Fund lifted its position in LivaNova by 28.6% during the first quarter. New York State Common Retirement Fund now owns 48,290 shares of the company’s stock worth $1,897,000 after purchasing an additional 10,733 shares during the period. CWM LLC boosted its holdings in shares of LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after purchasing an additional 299 shares in the last quarter. Foundry Partners LLC acquired a new position in LivaNova during the 1st quarter worth approximately $3,816,000. Finally, Allianz Asset Management GmbH bought a new position in LivaNova in the first quarter valued at about $593,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.